Two Tamiflu Licensees Prepare Production For Domestic Needs
This article was originally published in PharmAsia News
Executive Summary
Shanghai Pharmaceutical Group and Guangdong-based HEC Group, which received Tamiflu manufacturing authentication from Roche, are stepping up preparation for the drug's production. With an output of 40,000 tablets per day, SPG has completed raw material purchase and storage. Its two subsidiaries Hualian Pharmaceutical and Sunway Biotech will be in charge of formulation and pharmaceutical production, respectively. The group has passed 5,000 boxes of its Tamiflu stock to Shanghai municipal government and received a further order of 10,000 boxes from the government. HEC Group currently relies on its existing drug reserves and is gearing up for production. A local Tamiflu shortage exists due to Roche's restriction on sales and output capacity, which can only meet government's requirements. (Click here for more - Chinese language)
|
Shanghai Pharmaceutical Group and Guangdong-based HEC Group, which received Tamiflu manufacturing authentication from Roche, are stepping up preparation for the drug's production. With an output of 40,000 tablets per day, SPG has completed raw material purchase and storage. Its two subsidiaries Hualian Pharmaceutical and Sunway Biotech will be in charge of formulation and pharmaceutical production, respectively. The group has passed 5,000 boxes of its Tamiflu stock to Shanghai municipal government and received a further order of 10,000 boxes from the government. HEC Group currently relies on its existing drug reserves and is gearing up for production. A local Tamiflu shortage exists due to Roche's restriction on sales and output capacity, which can only meet government's requirements. (Click here for more - Chinese language) "Shanghai Pharmaceutical Group Schedules Tamiflu Production To Meet Domestic Demand" - China Business News (Shanghai) (5/7/09) |